NCT02452385

Phase 1 Study of CM082 in Patients With wAMD

Phase 1 Study of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy

• Status: Suspended
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: AnewPharma · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.

Detailed description

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD. Patients will receive one of four doses for up to four weeks. Single/multiple dose pharmacokinetics in these patients will be studied. At the end of four weeks, investigator will evaluate safety and tolerability and decide whether to continue treatment for a total of six months to further evaluate safety and preliminary efficacy.

Conditions

• Age-Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	CM082 tablet	CM082 tablets taken orally

Timeline

• Start date: 2015-03-01
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2015-05-22
• Last updated: 2020-01-13

Locations

6 sites across 1 country: China